These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1608280)

  • 21. [The clinical evaluation of psychopharmaceuticals in internal and general medicine. Elements for continuing psychopharmacologic and research education of the primary care physician].
    Castillo Pérez P
    An Med Interna; 1988 Sep; 5(9):471-81. PubMed ID: 2856628
    [No Abstract]   [Full Text] [Related]  

  • 22. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacy standards for clinical trials].
    Terkola R
    Onkologie; 2008; 31 Suppl 2():25-8. PubMed ID: 18487865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The Medical Products Agency's preparations prior to the new EU regulation on children and drugs].
    Johannesson M; Berglund EG
    Lakartidningen; 2007 Jul 11-24; 104(28-29):2099. PubMed ID: 17702388
    [No Abstract]   [Full Text] [Related]  

  • 25. View from the Nation's Capital. "Off-label" uses of approved drugs: limits on physicians' prescribing behavior.
    Appler WD; McMann GL
    J Clin Psychopharmacol; 1989 Oct; 9(5):368-70. PubMed ID: 2794099
    [No Abstract]   [Full Text] [Related]  

  • 26. [The Medical Products Agency is responsible for the control of medical technological products: we need more active medical professionals reporting shortages].
    Philipson L
    Lakartidningen; 2008 Mar 5-11; 105(10):746-7. PubMed ID: 18422241
    [No Abstract]   [Full Text] [Related]  

  • 27. Trials and tribulations: a primer on successfully navigating the waters of the Food and Drug Administration.
    Feinsod M; Chambers WA
    Ophthalmology; 2004 Oct; 111(10):1801-6. PubMed ID: 15465539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Structured introduction of new drug therapies: valuable initiative--transparency required].
    Lundkvist J; Henriksson F
    Lakartidningen; 2009 Jan 7-13; 106(1-2):51. PubMed ID: 19235324
    [No Abstract]   [Full Text] [Related]  

  • 29. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 30. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
    Müller L; Singer T
    Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 32. Risk management and post-marketing surveillance of CNS drugs: an introduction.
    Balster RL; Johanson CE; Walsh SL
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S1-3. PubMed ID: 19744805
    [No Abstract]   [Full Text] [Related]  

  • 33. Guidelines for the procurement of investigational and emergency drugs.
    Madsen M
    Can J Hosp Pharm; 1988 Oct; 41(5):275-6. PubMed ID: 10290647
    [No Abstract]   [Full Text] [Related]  

  • 34. A survey of pharmacy-coordinated investigational drug services.
    Cipywnyk DM; McBride J
    Can J Hosp Pharm; 1991 Aug; 44(4):183-8, 200. PubMed ID: 10112895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deficiencies in proposed new EU regulation of clinical trials.
    Gøtzsche PC
    BMJ; 2012 Dec; 345():e8522. PubMed ID: 23258926
    [No Abstract]   [Full Text] [Related]  

  • 36. [Recent initiatives of the European Union on the field of drug use and trafficking].
    Salazar L
    Ann Ist Super Sanita; 2002; 38(3):319-21. PubMed ID: 12645184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insomnia market.
    Gershell L
    Nat Rev Drug Discov; 2006 Jan; 5(1):15-6. PubMed ID: 16485342
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical trials committees: how long is the protocol review and approval process in Spain? A prospective study.
    Ortega R; Dal-Ré R
    IRB; 1995; 17(4):6-9. PubMed ID: 11654218
    [No Abstract]   [Full Text] [Related]  

  • 39. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baxter withdraws dialyser after 12 patients die.
    Bosch X
    BMJ; 2001 Sep; 323(7312):529. PubMed ID: 11546686
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.